Related references
Note: Only part of the references are listed.The Interplay between Uremic Toxins and Albumin, Membrane Transporters and Drug Interaction
Regiane Stafim da Cunha et al.
TOXINS (2022)
Transporters in Regulatory Science: Notable Contributions from Dr. Giacomini in the Past Two Decades
Lei Zhang et al.
DRUG METABOLISM AND DISPOSITION (2022)
Endogenous Plasma Kynurenic Acid in Human: A Newly Discovered Biomarker for Drug-Drug Interactions Involving Organic Anion Transporter 1 and 3 Inhibition
Jennifer Tang et al.
DRUG METABOLISM AND DISPOSITION (2021)
Coordinate regulation of systemic and kidney tryptophan metabolism by the drug transporters OAT1 and OAT3
Jeffry C. Granados et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2021)
Changes of Transporters and Drug-metabolizing Enzymes in Nephrotic Syndrome
Yaqian Dong et al.
CURRENT DRUG METABOLISM (2020)
An LC-MS/MS analytical method for the determination of uremic toxins in patients with end-stage renal disease
Yan-rong Ma et al.
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS (2020)
Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond
Michael Platten et al.
NATURE REVIEWS DRUG DISCOVERY (2019)
Kidney Cortical Transporter Expression across Species Using Quantitative Proteomics
Abdul Basit et al.
DRUG METABOLISM AND DISPOSITION (2019)
Proximal Tubular Secretory Clearance A Neglected Partner of Kidney Function
Ke Wang et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2018)
Renal tubule injury: a driving force toward chronic kidney disease
Bi-Cheng Liu et al.
KIDNEY INTERNATIONAL (2018)
Biomarkers for In Vivo Assessment of Transporter Function
Fabian Mueller et al.
PHARMACOLOGICAL REVIEWS (2018)
Clinical Probes and Endogenous Biomarkers as Substrates for Transporter Drug-Drug Interaction Evaluation: Perspectives From the International Transporter Consortium
Xiaoyan Chu et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2018)
Endogenous Probes for Drug Transporters: Balancing Vision With Reality
A. D. Rodrigues et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2018)
Identification of Endogenous Biomarkers to Predict the Propensity of Drug Candidates to Cause Hepatic or Renal Transporter-Mediated Drug-Drug Interactions
Xiaoyan Chu et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2017)
Chromatographic analysis of tryptophan metabolites
Ilona Sadok et al.
JOURNAL OF SEPARATION SCIENCE (2017)
Bioengineered kidney tubules efficiently excrete uremic toxins
J. Jansen et al.
SCIENTIFIC REPORTS (2016)
Molecular Properties of Drugs Interacting with SLC22 Transporters OAT1, OAT3, OCT1, and OCT2: A Machine-Learning Approachs
Henry C. Liu et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2016)
Investigation of Endogenous Compounds Applicable to Drug-Drug Interaction Studies Involving the Renal Organic Anion Transporters, OAT1 and OAT3, in Humans
Yuri Tsuruya et al.
DRUG METABOLISM AND DISPOSITION (2016)
Coproporphyrins in Plasma and Urine Can Be Appropriate Clinical Biomarkers to Recapitulate Drug-Drug Interactions Mediated by Organic Anion Transporting Polypeptide Inhibition
Yurong Lai et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2016)
Identification of new MRP4 inhibitors from a library of FDA approved drugs using a high-throughput bioluminescence screen
Leanna Cheung et al.
BIOCHEMICAL PHARMACOLOGY (2015)
N1-methylnicotinamide as an endogenous probe for drug interactions by renal cation transporters: studies on the metformin-trimethoprim interaction
Fabian Mueller et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2015)
Utility of Bilirubins and Bile Acids as Endogenous Biomarkers for the Inhibition of Hepatic Transporters
Tomoko Watanabe et al.
DRUG METABOLISM AND DISPOSITION (2015)
Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions
Jason A. Roberts et al.
LANCET INFECTIOUS DISEASES (2014)
The Kidney and Uremic Toxin Removal: Glomerulus or Tubule?
Rosalinde Masereeuw et al.
SEMINARS IN NEPHROLOGY (2014)
Serum cystatin C predicts vancomycin trough levels better than serum creatinine in hospitalized patients: a cohort study
Erin N. Frazee et al.
CRITICAL CARE (2014)
6β-Hydroxycortisol Is an Endogenous Probe for Evaluation of Drug-Drug Interactions Involving a Multispecific Renal Organic Anion Transporter, OAT3/SLC22A8, in Healthy Subjects
Yuichiro Imamura et al.
DRUG METABOLISM AND DISPOSITION (2014)
Renal Transporters in Drug Development
Kari M. Morrissey et al.
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, VOL 53, 2013 (2013)
Can Drug Interactions Be Evaluated by Monitoring Plasma Drug Concentrations?
Toshiyuki Kume
DRUG METABOLISM AND PHARMACOKINETICS (2013)
Effect of the Fluoroquinolone Antibacterial Agent DX-619 on the Apparent Formation and Renal Clearances of 6β-Hydroxycortisol, an Endogenous Probe for CYP3A4 Inhibition, in Healthy Subjects
Yuichiro Imamura et al.
PHARMACEUTICAL RESEARCH (2013)
Glomerular Filtration Rate Equations Overestimate Creatinine Clearance in Older Individuals Enrolled in the Baltimore Longitudinal Study on Aging: Impact on Renal Drug Dosing
Thomas C. Dowling et al.
PHARMACOTHERAPY (2013)
Interaction of immunosuppressive drugs with human organic anion transporter (OAT) 1 and OAT3, and multidrug resistance-associated protein (MRP) 2 and MRP4
Azza A. K. El-Sheikh et al.
TRANSLATIONAL RESEARCH (2013)
Protein-bound uremic toxins in hemodialysis patients measured by liquid chromatography/tandem mass spectrometry and their effects on endothelial ROS production
Yoshiharu Itoh et al.
ANALYTICAL AND BIOANALYTICAL CHEMISTRY (2012)
Expression of Organic Anion Transporter 2 in the Human Kidney and Its Potential Role in the Tubular Secretion of Guanine-Containing Antiviral Drugs
Yaofeng Cheng et al.
DRUG METABOLISM AND DISPOSITION (2012)
Evaluation of 6β-Hydroxycortisol, 6β-Hydroxycortisone, and a Combination of the Two as Endogenous Probes for Inhibition of CYP3A4 In Vivo
C-C Peng et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2011)
Untargeted Metabolomics Identifies Enterobiome Metabolites and Putative Uremic Toxins as Substrates of Organic Anion Transporter 1 (Oat1)
William R. Wikoff et al.
JOURNAL OF PROTEOME RESEARCH (2011)
Organic anion transporters play an important role in the uptake of p-cresyl sulfate, a uremic toxin, in the kidney
Yohei Miyamoto et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2011)
Antibiotics in critically ill patients: a systematic review of the pharmacokinetics of beta-lactams
Joao Goncalves-Pereira et al.
CRITICAL CARE (2011)
Physiologically Based Pharmacokinetic Modeling to Predict Transporter-Mediated Clearance and Distribution of Pravastatin in Humans
Takao Watanabe et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2009)
Drug and toxicant handling by the OAT organic anion transporters in the kidney and other tissues
Sanjay K. Nigam et al.
NATURE CLINICAL PRACTICE NEPHROLOGY (2007)
Functional involvement of multidrug resistance-associated protein 4 (MRP4/ABCC4) in the renal elimination of the antiviral drugs adefovir and tenofovir
Tomoki Imaoka et al.
MOLECULAR PHARMACOLOGY (2007)
Decreased renal organic anion secretion and plasma accumulation of endogenous organic anions in OAT1 knock-out mice
SA Eraly et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
The impact of plasma protein binding on the renal transport of organic anions
DAJ Bow et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2006)
Molecular cloning and functional analyses of OAT1 and OAT3 from cynomolgus monkey kidney
H Tahara et al.
PHARMACEUTICAL RESEARCH (2005)
Differential contributions of rOat1 (Slc22a6) and rOat3 (Slc22a8) to the in vivo renal uptake of uremic toxins in rats
T Deguchi et al.
PHARMACEUTICAL RESEARCH (2005)
Characterization of uremic toxin transport by organic anion transporters in the kidney
T Deguchi et al.
KIDNEY INTERNATIONAL (2004)
Contribution of multidrug resistance protein 2 (MRP2/ABCC2) to the renal excretion of p-aminohippurate (PAH) and identification of MRP4 (ABCC4) as a novel PAH transporter
PHE Smeets et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2004)
Principles and clinical application of assessing alterations in renal elimination pathways
SE Tett et al.
CLINICAL PHARMACOKINETICS (2003)
Share Paper
